These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32842052)

  • 1. Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial.
    Liu JH; Black DR; Larkin L; Graham S; Bernick B; Mirkin S
    Menopause; 2020 Dec; 27(12):1388-1395. PubMed ID: 32842052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.
    Kaunitz AM; Bitner D; Constantine GD; Bernick B; Graham S; Mirkin S
    Menopause; 2020 Dec; 27(12):1382-1387. PubMed ID: 32740481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
    Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
    Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).
    Lobo RA; Liu J; Stanczyk FZ; Constantine GD; Pickar JH; Shadiack AM; Bernick B; Mirkin S
    Menopause; 2019 Jul; 26(7):720-727. PubMed ID: 30694918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause.
    Archer DF; Bernick BA; Mirkin S
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):729-739. PubMed ID: 31282768
    [No Abstract]   [Full Text] [Related]  

  • 6. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
    Lobo RA; Archer DF; Kagan R; Kaunitz AM; Constantine GD; Pickar JH; Graham S; Bernick B; Mirkin S
    Obstet Gynecol; 2018 Jul; 132(1):161-170. PubMed ID: 29889748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.
    Constantine GD; Simon JA; Kaunitz AM; Pickar JH; Revicki DA; Graham S; Bernick B; Mirkin S
    Menopause; 2020 Nov; 27(11):1236-1241. PubMed ID: 33110039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR).
    Mirkin S; Goldstein SR; Archer DF; Pickar JH; Graham S; Bernick B
    Menopause; 2020 Apr; 27(4):410-417. PubMed ID: 31913228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.
    Mirkin S; Graham S; Revicki DA; Bender RH; Bernick B; Constantine GD
    Menopause; 2019 Jan; 26(6):637-642. PubMed ID: 30601452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms.
    Lobo RA; Kaunitz AM; Santoro N; Bernick B; Graham S; Mirkin S
    Climacteric; 2019 Dec; 22(6):610-616. PubMed ID: 31364889
    [No Abstract]   [Full Text] [Related]  

  • 11. Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women.
    Kagan R; Constantine G; Kaunitz AM; Bernick B; Mirkin S
    Menopause; 2018 Dec; 26(6):622-628. PubMed ID: 30586005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioidentical Oral 17β-Estradiol and Progesterone for the Treatment of Moderate to Severe Vasomotor Symptoms of Menopause.
    Woodis CB; Ghassemi E; McLendon AN
    Ann Pharmacother; 2021 Sep; 55(9):1153-1158. PubMed ID: 33345556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
    Constantine GD; Revicki DA; Kagan R; Simon JA; Graham S; Bernick B; Mirkin S
    Menopause; 2019 May; 26(5):513-519. PubMed ID: 30516713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combined 17β-estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial.
    Black DR; Minkin MJ; Graham S; Bernick B; Mirkin S
    Menopause; 2020 Sep; 28(1):32-39. PubMed ID: 32932401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review.
    Mirkin S; Amadio JM; Bernick BA; Pickar JH; Archer DF
    Maturitas; 2015 May; 81(1):28-35. PubMed ID: 25835751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioidentical hormones for women with vasomotor symptoms.
    Gaudard AM; Silva de Souza S; Puga ME; Marjoribanks J; da Silva EM; Torloni MR
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010407. PubMed ID: 27479272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms.
    McClung MR; Kagan R; Graham S; Bernick B; Mirkin S; Constantine G
    Menopause; 2022 Feb; 29(3):304-308. PubMed ID: 35213517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
    Archer DF; Schmelter T; Schaefers M; Gerlinger C; Gude K
    Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial 17beta-estradiol dose for treating vasomotor symptoms.
    Notelovitz M; Lenihan JP; McDermott M; Kerber IJ; Nanavati N; Arce J
    Obstet Gynecol; 2000 May; 95(5):726-31. PubMed ID: 10775738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.